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Abstract
Background: Chlamydia trachomatis (CT) infection is common and largely asymptomatic in 
women. If untreated it can lead to sequelae such as pelvic inflammatory disease and infertility. It is 
unknown if a patient’s self-reported history of CT infection is a valid marker of past infection.
Objective: Our objective was to evaluate the validity of women’s self-reported history of CT 
infection compared to CT serology, a marker for previous infection.
Study Design: We analyzed data from the Fertility After Contraception study. We compared 
participants’ survey responses to the question, “Have you ever been told by a healthcare provider 
that you had Chlamydia?” to serological test results indicating the presence or absence of 
antibodies to CT as assessed by microimmunofluorescence (MIF) assay. Prevalence of past 
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infection, sensitivity, specificity, predictive values, and likelihood ratios were calculated. Cohen’s 
kappa statistic was computed to assess agreement between self-report and serology.
Results: Among 409 participants, 108 (26%) reported having a history of CT infection, whereas 
146 (36%) had positive serological test results. Relative to positive MIF assay, the sensitivity and 
specificity of self-reported history of CT infection were 52.1% (95% CI, 43.6%, 60.4%) and 
87.8% (95% CI, 83.3%, 91.5%), respectively. Positive predictive value of self-report was 70.4% 
(95% CI, 60.8%, 78.8%), and the negative predictive value was 76.7% (95% CI, 71.6%, 81.4%). 
The likelihood ratio was found to be 4.28. Agreement between self-report and serology was found 
to be moderate (kappa = 0.42, P < 0.001).
Conclusion: Self-reported history of CT infection commonly yields false negative and false 
positive results. When definitive status of past CT infection is needed, serology should be 
obtained.
Condensation:
Self-reported history of Chlamydia trachomatis infection has limited validity as a measure of a 
patient’s past exposure to chlamydial infection.
Keywords
Chlamydia trachomatis; microimmunofluorescence assay; self-report; serology; sexually 
transmitted infection; validity
INTRODUCTION
Chlamydia trachomatis (CT) infection is the most common notifiable sexually transmitted 
infection (STI) in the United States and is largely asymptomatic. Up to 80% of women with 
CT infections experience no symptoms.1,2 If CT infections are not diagnosed and treated in 
a timely manner, these infections can progress and lead to pelvic inflammatory disease 
(PID), chronic pelvic pain, and infertility. Healthcare providers may ask about previous CT 
infection while taking a medical history, but it is unclear to what degree a self-reported 
history of CT infection is a valid measure of past infection.
Although the literature contains several studies assessing the validity of self-reported STIs, 
few studies specifically evaluate the validity of self-reported CT infection.3,4 One 
randomized controlled trial for a STI intervention program found that only 68% of African-
American, female teenagers with a laboratory confirmed CT infection correctly reported 
their history of infection one month after learning of their diagnosis.5 A study performed by 
Niccolai et al. compared female adolescents’ self-reported CT diagnoses to a composite 
reference standard defined as positive if either the participant’s medical record or a state 
health department report showed the patient to have a history of CT infection. This study 
found a high specificity of 97.3% and a sensitivity of 69.1%.6
The purpose of this analysis is to evaluate the validity of women’s self-reported history of 
CT infection compared to CT serology as assessed by microimmunofluorescence (MIF), a 
sensitive marker for previous infection with CT.7 Self report and serology may not agree for 
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many reasons, including lack of understanding of test results, desire to not disclose a history 
of positive test results, and the absence of prior testing, either due to the asymptomatic 
nature of the infection or lack of access to testing. Given all these complexities surrounding 
self-reported history of CT infections, we hypothesize that women will significantly 
underestimate their history of past infection and that a reported history of CT infection is not 
a reliable marker of past infection.
MATERIALS AND METHODS
We performed a cross-sectional analysis of the Fertility After Contraception Termination 
(FACT) study. FACT is a prospective cohort study developed primarily to assess the role of 
infection and contraceptive use (specifically intrauterine device (IUD) use) on fertility. We 
compared self-reported CT infection to serologic results obtained at the time of baseline 
interview and evaluation.
Many of the FACT participants were recruited from the Contraceptive CHOICE Project, a 
prospective cohort study of 9,256 women in the St. Louis area who were provided with no-
cost contraception for 2–3 years. A more in-depth methodological description of the 
CHOICE project has been previously described.8 We augmented our sample size with 
recruitment from four additional clinical research programs (University of Pennsylvania, 
University of Colorado, University of Utah, and University of Southern California). 
Institutional review boards at all participating institutions approved this study, and written 
informed consent was obtained from all participants prior to study involvement.
English- or Spanish-speaking women between the ages of 18 to 35 were eligible for the 
study if they were discontinuing a contraceptive method to attempt pregnancy. Women were 
excluded if they met the following criteria: (1) were pregnant at time of enrollment; (2) did 
not have a male partner at time of enrollment; (3) were going to be physically separated 
from their male partner for six months or longer; (4) were with a male partner who has a 
history of vasectomy, infertility, or abnormal semen analysis; (5) had a history of infertility, 
tubal reconstructive surgery, or sterilization; or (6) had medical problems known to affect 
fertility (e.g., cancer therapy, thyroid problems, Cushing’s disease, sickle cell disease, 
kidney disease, and diabetes).
Baseline investigations included a questionnaire, a clinical exam, blood samples for 
serologic testing for CT, Mycoplasma genitalium (MG), and Trichomonas vaginalis (TV), 
and nucleic acid amplification testing (NAAT, APTIMA, Gen-Probe) for current STIs 
(Neisseria gonorrhoeae, CT, TV, and MG). Although both serology and nucleic acid 
amplification testing were available for CT, MG, and TV, we decided to focus our study on 
CT given that it is the most common nationally notifiable sexually transmitted disease and it 
is likely a more well-known STI compared to MG or TV. Baseline data collection included 
demographic, historical, medical/surgical history, and reproductive characteristics. As part of 
the baseline questionnaire, participants were asked if they have ever been told by a 
healthcare provider that they had chlamydia. Participants’ “yes” or “no” answers to this 
question represented their self-reported history of CT infection.
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The serological samples taken at baseline were used to assess current and/or previous CT 
infection. The samples were clarified by centrifugation, aliquotted, and frozen at −80°C. 
Samples were then transported on dry ice to the University of Washington Chlamydia 
Laboratory for analysis using the microimmunofluorescence assay developed by Wang et al. 
as modified by Hanna and Keshishyan.9,10 All serologic assays were performed by the same 
experienced technician. Based on a previous receiver operating characteristic curve analysis 
of CT antibody titers and laparoscopically-confirmed tuboperitoneal abnormalities, we 
considered a titer of 1:16 as evidence of a positive history of CT infection.11 While previous 
studies have used cutoff dilutions ranging from 1:8 to 1:640, not all used the same technique 
or staff to perform this technically complicated assay.12
Only those participants whose serologic results were returned by the time of analysis were 
included. Dates of data collection for this analysis ranged from September 8, 2011 to 
February 25, 2016. Baseline demographic characteristics of this sample were compared 
using chi-square, Fisher exact, and Student’s t–tests, as appropriate. Prevalence of past 
infection was calculated using the serological data. Sensitivity, specificity, predictive values, 
and positive likelihood ratio for self-reported history of infection were also calculated. 
Cohen’s kappa statistic was calculated to assess agreement between self-report and serology. 
Bivariate logistic regression analysis was performed to assess the association between the 
baseline demographic characteristics and self-reported CT history and serologic CT results. 
All statistical analyses were performed using SAS 9.4 software. The significance level of 
alpha was set at 0.05.
RESULTS
At the time of data analysis, 440 women had enrolled in FACT. A total of 432 participants 
responded to the question “Have you ever been told by a healthcare provider that you had 
chlamydia”, and 420 had serologic data available. Four hundred and nine participants had 
both data points available and are included in our data analysis.
The baseline demographic, reproductive, and behavioral characteristics by self-reported 
history of CT infection and serologic status are provided in Table 1. The mean age of 
participants was 28 years. Forty-two percent of participants were black, 8% reported 
Hispanic ethnicity, 57% were married, 22% had a high school education or less, 38% were 
of low socioeconomic status, 36% smoked, 14% used drugs, and 24% had no insurance. 
Seventeen participants (4.2%) had positive CT test results at the baseline encounter. 
Participants with a positive self-reported or serologically confirmed history of CT were more 
likely to be younger, higher gravidity, non-white, unmarried, of lower educational level and 
SES, former implant or depo-medroxyprogesterone acetate (DMPA) users, uninsured, and a 
current drug user.
Table 2 compares self reported CT infection to serologic status. Twenty-six percent of 
participants reported having a history of CT infection whereas 36% of participants had 
positive serological test results. . Of the 146 women who had antibodies to CT, 76 reported a 
history of CT infection. Conversely, of the 263 women who had no antibodies to CT, 231 
reported never having a CT infection in the past. The sensitivity and specificity of women’s 
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self-reported history of CT infection were 52.1% (95% confidence interval (CI), 43.6%, 
60.4%) and 87.8% (95% CI, 83.3%, 91.5%), respectively. Positive predictive value of self-
report was 70.4% (95% CI, 60.8%, 78.8%), and the negative predictive value was 76.7% 
(95% CI, 71.6%, 81.4%). The positive likelihood ratio was found to be 4.28. The agreement 
between self-reported history of CT infection and serological testing was calculated using 
Cohen’s kappa statistic. The tests show moderate agreement (kappa = 0.42, P < 0.001).
The results of our multivariable logistic regression model of predictors of self-reported CT 
history and positive CT serology are shown in Table 3. Young age, non-white race, 
unmarried marital status, lower education and SES, implant use, non-private insurance, 
poorer health, current drug use, and young age at first pregnancy were associated with both 
self-reported history of CT and serologic positivity.
COMMENT
Self-report is an affordable and convenient way to assess a patient’s history of CT infection, 
yet few studies have examined its validity. When evaluating validity of self-report in women 
enrolled in the FACT study, we found self-report to not be a valid marker of past CT 
infection status. Only 52% of women with positive serology reported a history of CT 
infection. This low sensitivity indicates a high false negative rate. Specificity was higher at 
88%, indicating a false positive rate of 12%. Our positive and negative predictive values of 
self reported CT infection were 70% and 77%, respectively. Thus, 30% of participants who 
reported a history of CT infection did not have a history of infection according to serology, 
and almost 25% of participants who reported not having a history of CT infection actually 
had serologic evidence of infection. In addition, the likelihood ratio of 4.28 only shows a 
moderate increase in the likelihood of past disease given positive self-report. The Cohen’s 
Kappa of 0.4 indicates a moderate level of agreement between self-report and serology.13
There are several explanations as to why women would report no history of CT infection in 
the setting of positive serology. Since most CT infections are asymptomatic, it is possible 
that these women never sought out testing or were not appropriately screened per current 
guidelines.14 Even if participants were symptomatic, they may not have sought or received 
testing. It is also possible that participants who have received CT testing in the past did not 
receive, remember, or understand the results of this testing. Lastly, participants may have 
decided not to disclose their history of CT infection.
There are several reasons why participants may have reported a history of CT infection in 
the setting of negative serology. Studies have shown that women have many misconceptions 
regarding STI testing. One study found that 32% of participants thought visual inspection by 
a provider was a valid method to screen for CT infection, and 26% believed that 
Papanicolaou tests screen for CT infection.15 In this context, it is possible that some 
participants misunderstood what reproductive health testing they received in the past and/or 
the results of those tests. It is also possible that some participants may have mistaken an 
alternative STI diagnosis as CT.
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This study found a surprising association between self-reported and serologically confirmed 
CT infection and contraceptive implant use. It is possible that this association is mediated by 
age. The contraceptive implant is a popular choice of birth control among young women and 
young women below the age of 24 are at highest risk for CT infection.16,17 It is unlikely that 
this association is due to changes in sexual activity among women who use the contraceptive 
implant.18
Our study has several strengths. First, the broad age range of participants, 18 to 35 years of 
age, and the geographic distribution of participants adds to the generalizibility of our 
findings. Second, our use of serology as a marker of past infection is a major strength. The 
microimmunofluorescence assay is a sensitive assay for past infection as antibodies to CT 
may persist for many years even after antibiotic treatment.19–21 It also requires a high degree 
of technical skill, and all of the assays in this study were performed by a single technician 
with decades of experience in this technique. Third, our study population includes women 
who may not have been previously tested for CT infection. This differs from the study 
populations in the available literature. Participants in the Harrington et al study were tested 
for CT, informed of their results, and later asked to recall these results.5 The Niccolai study 
used a composite reference standard defined as positive if either the participant’s medical 
record or a state health department report showed the patient to have a history of CT 
infection.6 This choice of reference standard limits the participants to those who have been 
tested for CT as participants without any records were excluded from analysis. Therefore our 
study population may be more generalizable as healthcare providers cannot assume 
ubiquitous testing in a majority of clinical populations in the United States.
Limitations of the current study include our use of a 1:16 cutoff to define positive serology. 
Our decision to use this cutoff is well supported by the literature and our experience with 
this assay in the laboratory.11 Our choice of cutoff informs the prevalence of positive 
serology, 36%, seen in this study. The use of a greater dilution to define positive serologic 
results would likely lead to a lower calculated prevalence, a lower positive predictive value, 
and a higher negative predictive value. In addition, the generalizibility of our findings may 
be limited in that women in the FACT study were all attempting to conceive.
In conclusion, self-reported history of CT infection has limited validity. Our findings have 
both clinical and public health implications. Many healthcare providers rely on patient 
reported history of previous CT infection to assess previous infection status. Our results 
suggest that self-report may not be reliable. In clinical assessments requiring high validity, 
such as in fertility assessments, serology should be considered. Our results also suggest a 
need for improved patient education. Patients should be provided information regarding the 
testing they are receiving, informed of the results of those tests, and understand the test 
results and their implications.
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Table 2.
Serologic status by self-reported history of CT infection
Positive Serology Negative Serology
(n=146) (n=263)
Positive Self-Report (n=108) 76 32
Negative Self-Report (n=301) 70 231
Sensitivity = 52.1% (95% CI, 43.6%, 60.4%)
Specificity = 87.8% (95% CI, 83.3%, 91.5%)
Positive Predictive Value = 70.4% (95% CI, 60.8%, 78.8%)
Negative Predictive Value = 76.7% (95% CI, 71.6%, 81.4%)
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Table 3.
Adjusted odds ratios of baseline variables and self-reported history of CT infection and serologic results from 
multivariable logistic regression model.
Self-Reported CT History
OR 195% Cl)
Serology CT History
OR (95% Cl)
Age (y) 0.89 (0.83, 0.93) 0.89 (0.85, 0.94)
Race
  White Ref Ref
  Black 8.06 (4.64, 14.00) 9.53 (5.80,15.67)
  Other/Multl-raaal 3.38(1.33, 8.58) 3.40 (1.47, 7.85)
Hispanic ethnicity
  No Ref Ref
  Yes 1.05 (0.47, 2.33) 0.56 (0.19,1.08)
Marital Status
  Married Ref Ref
  Living with partner 7.32 (4.06,13.18) 7.31 (4.15,12.89)
  Single/Divorced/Widowed 4.29 (2.45, 7.49) 4.72 (2.83, 7.89)
Education
  HS diploma, GED, or less Ref Ref
  Some college 0.76 (0.44,1.30) 0.91 (0.53,1.57)
  College or graduate degree 0.10 (0.05, 0.19) 0.13 (0.07,0.24)
Low SES*
  No Ref Ref
  Yes 4.12 (2.59, 6.55) 5.90 (3.78,9.19)
Most Recent Birth Control Method
  Non-LARC Ref Ref
  IUD 1.31 (0.75, 2.27) 1.82 (1.11, 3.00)
  Implant 3.65 (1.93, 6.89) 3.08 (1.68,5.66)
Insurance
  Private Ref Ref
  Public 5.33 (2.86, 9.90) 5.79 (3.18,10.57)
  None 4.87(2.86, 8.30) 5.46(3.30,9.05)
General Health†
  Excellent to very good Ref Ref
  Good  2.46(1.51, 4.00) 2.37 (1.51, 3.72)
  Fair to poor 10.12 (4.16, 24.64) 6.00(2.50, 14.40)
Current smoker
  No Ref Ref
  Yes 1.58(0.78,3.23) 1.96(1.00, 3.87)
Current drug use
  No Ref Ref
  Yes 1.88(1.05, 3.38) 2.56(1.46, 4.50)
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Self-Reported CT History
OR 195% Cl)
Serology CT History
OR (95% Cl)
Gravidity
  0 Ref Ref
  1–2 3.02(1.73,5.29) 3.57 (2.12, 6.01)
  >3 3.21 (1.69, 6.08) 5.31(2.92,9.64)
Age at first pregnancy 0.91(0.85, 0.97) 0.87 (0.82, 0.93)
*
Defined as receipt of public assistance or report of difficulty paying for basic necessities.
†Assessed with the following question: “in general would you say your health is excellent, very good, fair, or poor?”
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